Antibody Detection for Anti-Drug Resistance-Associated Mutations in SARS-CoV-2 (Nucleocapsid Protein)
This test checks for antibodies against specific mutations linked to resistance in the SARS-CoV-2 virus’s nucleocapsid protein, which may affect how your body responds to COVID-19 treatments.
["Helps monitor potential resistance to vaccines or therapies by detecting rare viral changes."]
Key facts at a glance
- LOINC
- 90807-9
- Short code
- CGLDNA
- Synonyms
- C glabrata DNA Ser Ql NAA+probe
- Category
- chemistry
- Sample
- serum
- Container
- Serum separator tube (SST) or sterile serum tube (red-top, no anticoagulant)
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- ≥ 0 years
- Method
- probe-amp-tar
- CPT
- 87481
- SNOMED
- 122450004
- Specimen volume
- 1-2 mL serum (minimum 0.5 mL)
- Stability
- Stable for 24 hours at room temperature (20-25°C), 7 days refrigerated at 2-8°C, and up to 4 weeks frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 8–72 hours
- Order
- routine
Why This Test Might Be Ordered
Your healthcare provider may recommend this test if you’ve had COVID-19 recently, are on long-term antiviral treatment, or if you’re at higher risk for treatment resistance. It’s not a routine screening test for most people.
What to Expect Before the Test
No special preparation is needed. A blood sample will be drawn from a vein, similar to other blood tests. The sample is processed to detect antibodies against specific viral mutations.
What the Results Mean
Positive results indicate the presence of antibodies against these mutations, which may suggest a higher likelihood of resistance. Negative results mean these antibodies were not detected in your sample.
Common Reasons for Testing
This test is primarily used in clinical research or specialized care settings to assess how certain viral mutations might impact treatment efficacy in patients with chronic or recurrent COVID-19.
Reference range
Negative (not detected) for Candida glabrata DNA in serumN/A
No special patient preparation or fasting required. Sample should be collected prior to initiation of antifungal therapy when possible to maximize diagnostic yield.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
Clinical Significance: This test is not a standard diagnostic tool but may be used in research or advanced treatment monitoring to identify mutations associated with drug resistance in SARS-CoV-2. Results help guide personalized treatment plans for patients with persistent or recurrent infections.
Short name
Anti-Nucleocapsid Antibody (Drug Resistance Screening)
Frequently asked questions
Will this test show if I have COVID-19 now?
What does a positive result mean for my treatment?
How often will I need this test?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy